Loading…
Lobbying Spend
—
Filings
76
Firms Hired
1
Active Period
2008–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Ensuring Patient Access to Critical Breakthrough Products Act
2026 · third_quarter · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2026 · third_quarter · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Client expense: — · Firm income: $30,000
Matched citations: S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act
2026 · second_quarter · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2026 · second_quarter · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Client expense: — · Firm income: $30,000
Matched citations: S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act
2026 · first_quarter · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2026 · first_quarter · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Client expense: — · Firm income: $30,000
Matched citations: S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act
2025 · fourth_quarter · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2025 · fourth_quarter · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Client expense: — · Firm income: $30,000
Matched citations: S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act
2025 · third_quarter · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2025 · third_quarter · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program.
Client expense: — · Firm income: $30,000
Matched citations: S. 1717
To amend title XVIII of the Social Security Act to limit the coinsurance amount for certain services furnished in an ambulatory surgical center.
2025 · second_quarter · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3006
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2025 · second_quarter · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Client expense: — · Firm income: $30,000
Matched citations: S. 1717
Medicare Beneficiary Co-Pay Fairness Act
2025 · second_quarter · Firm: THE MCMANUS GROUP
Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC), including S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025. Access to and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Medicare Beneficiary Co-Pay Fairness Act of 2025 (H.R. 3006/S. 1776)
Client expense: — · Firm income: $30,000
Matched citations: S. 1776
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
2024 · fourth_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023, and S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to reimbursement of medical devices in Medicare program including in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Client expense: — · Firm income: $30,000
Matched citations: H.R.10445
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · fourth_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023, and S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to reimbursement of medical devices in Medicare program including in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Client expense: — · Firm income: $30,000
Matched citations: H.R.1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · fourth_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023, and S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to reimbursement of medical devices in Medicare program including in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Client expense: — · Firm income: $30,000
Matched citations: S.5349
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · third_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Client expense: — · Firm income: $30,000
Matched citations: H.R.1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · second_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Client expense: — · Firm income: $40,000
Matched citations: H.R.1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · first_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Client expense: — · Firm income: $40,000
Matched citations: H.R.1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2023 · fourth_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Client expense: — · Firm income: $40,000
Matched citations: H.R.1691
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. H.R.1557 - BID Act of 2023, requiring the Secretary of Health and Human Services to submit a report on the interoperability of medical devices. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). Issues related to FY2024 Medicare Hospital Inpatient Prospective Payment System (IPPS)(CMS-1785-P)
Client expense: — · Firm income: $40,000
Matched citations: H.R.1557
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2023 · third_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. H.R.1557 - BID Act of 2023, requiring the Secretary of Health and Human Services to submit a report on the interoperability of medical devices. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). Issues related to FY2024 Medicare Hospital Inpatient Prospective Payment System (IPPS)(CMS-1785-P)
Client expense: — · Firm income: $40,000
Matched citations: H.R.1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2023 · second_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). Issues related to FY2024 Medicare Hospital Inpatient Prospective Payment System (IPPS)(CMS-1785-P)
Client expense: — · Firm income: $40,000
Matched citations: H.R.1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2023 · first_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $40,000
Matched citations: H.R.1691
Food and Drug Amendments of 2022
2022 · fourth_quarter · Firm: THE MCMANUS GROUP
Provisions included in S. 4348 - FDASLA Act of 2022 and H.R. 7667 - Food and Drug Amendments of 2022.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 7667
Source: Senate LDA